Alpha Tau Medical (DRTSW) Net Cash Flow (2021 - 2022)

Alpha Tau Medical (DRTSW) posted Net Cash Flow of -$86.3 million for Q2 2022, down 214.92% sequentially from $75.1 million in Q1 2022.

Alpha Tau Medical (DRTSW) Net Cash Flow (2021 - 2022) Analysis & Trends

Alpha Tau Medical has reported Net Cash Flow for 2 years, with the latest figure at -$86.3 million in Q2 2022.

Quarterly Net Cash Flow changed N/A year-over-year to -$86.3 million in Q2 2022, while the trailing twelve-month figure through Mar 2023 was -$86.3 million (down 214.92% YoY) and the FY2025 annual result came in at -$1.5 million, down 248.61% from the prior year.
Net Cash Flow fell to -$86.3 million in Q2 2022 per DRTSW's latest filing, from $75.1 million in the prior quarter.
Over five years, Net Cash Flow peaked at $75.1 million in Q1 2022 and troughed at -$86.3 million in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Cash Flow (Qtr)
1	Vertex Pharmaceuticals	139.79 Bn	131.94 Bn	2.84 Bn	652.90 Mn
2	Regeneron Pharmaceuticals	86.74 Bn	78.74 Bn	3.93 Bn	-504.30 Mn
3	Argenx Se	65.48 Bn	60.29 Bn	1.37 Bn	-
4	Moderna	59.32 Bn	54.18 Bn	52.00 Mn	-183.00 Mn
5	BeOne Medicines	42.08 Bn	36.98 Bn	1.53 Bn	407.41 Mn
6	Alnylam Pharmaceuticals	31.81 Bn	28.50 Bn	992.69 Mn	-496,000.00
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-2.83 Bn
8	Insmed	27.56 Bn	26.40 Bn	358.27 Mn	-37.14 Mn
9	Royalty Pharma	27.29 Bn	26.45 Bn	-	225.59 Mn
10	Alpha Tau Medical	362.22 Mn	179.81 Mn	-	-

Download Data